How large is the obstructive sleep apnea device market opportunity and what is sustaining its growth?
Obstructive sleep apnea is the single largest respiratory device therapy indication globally, with an estimated 936 million adults affected by moderate-to-severe OSA by International Sleep Medicine consensus criteria and the vast majority undiagnosed or untreated. Expanded home sleep testing accessibility using portable sleep monitoring devices approved for OSA diagnosis has reduced the polysomnography laboratory gatekeeping burden that historically constrained diagnosis and CPAP initiation rates. CPAP and APAP device adoption is further sustained by growing physician awareness of OSA-cardiovascular comorbidity associations that motivate active diagnosis and treatment, and by direct-to-consumer sleep apnea awareness campaigns that are increasing patient self-referral rates.

What is driving high-flow nasal cannula adoption above conventional oxygen therapy and CPAP in respiratory failure?
High-flow nasal cannula (HFNC) systems delivering heated, humidified oxygen-air blends at flows of 40 to 70 litres per minute provide oxygenation support superior to conventional low-flow oxygen masks at comparable or lower patient discomfort compared to CPAP masks, with evidence supporting HFNC use in acute hypoxaemic respiratory failure, post-extubation respiratory support, and COVID-19-related hypoxaemic respiratory failure as a bridge to or alternative to conventional oxygen therapy or non-invasive ventilation. HFNC is expanding from critical care ICU settings into step-down units, emergency departments, and home-based acute care programmes.

How are smart connected inhalers transforming asthma and COPD management?
Smart inhalers incorporating electronic sensors that detect and timestamp each actuation and transmit adherence and technique data to smartphone applications and physician dashboards are addressing the fundamental challenge in asthma and COPD management that approximately 50 percent of inhaler doses are missed and a majority of patients use incorrect inhaler technique. Randomised controlled trials of smart inhaler-supported management programmes demonstrate improvement in adherence rates, reduction in rescue inhaler use, and reduction in uncontrolled asthma exacerbation rates versus standard care, providing evidence supporting payer coverage and prescriber adoption of connected inhaler programmes.

What sustained home ventilator demand above pre-pandemic levels?
The COVID-19 pandemic generated acute critical care ventilator stockpiling by governments and hospital systems, but the more durable legacy effect on the respiratory care market has been the acceleration of home ventilator programme development for chronic respiratory failure patients with neuromuscular disease, chronic obstructive pulmonary disease with hypercapnic failure, and obesity hypoventilation syndrome who previously would have been managed in long-term acute care facilities. Home non-invasive ventilation programmes using bilevel devices and home ventilators with integrated monitoring have reduced rehospitalisation rates in chronic respiratory failure patients, creating payer alignment with home ventilator investment.

How is portable oxygen concentrator technology expanding patient mobility above stationary concentrator baseline?
Portable oxygen concentrator devices weighing less than 3 kilograms and operating from rechargeable lithium-ion battery packs for 4 to 8 hours of ambulatory use have enabled prescribed supplemental oxygen users to travel, exercise, and participate in activities that bulky stationary concentrators and compressed oxygen cylinders prevented. Airline approval for specific portable POC models has enabled supplemental oxygen users to travel by commercial air without hospital-supplied in-flight oxygen arrangements, materially improving quality of life and adherence to prescribed supplemental oxygen therapy.

Which respiratory care device segments are growing fastest?
Portable and home-based CPAP and APAP device adoption driven by expanded home sleep testing access, HFNC expanding from ICU into step-down and emergency respiratory failure management, smart connected inhaler programmes improving asthma and COPD management adherence, and portable oxygen concentrator enabling ambulatory oxygen therapy are the four fastest-growing respiratory care device segments.